BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the BD MAXTM GBS Assay for Group B Streptococcus (GBS) on the BD MAX™ System. The BD MAX System is a next-generation automated workstation for molecular testing designed to streamline workflow and offer full walkaway automation to accommodate varying workloads for maximum lab efficiency and flexibility.
"The BD MAX GBS assay is the first test in a complementary menu to BD's infectious diseases portfolio," said Philippe Jacon, President, BD Diagnostics - Diagnostic Systems. "This achievement further demonstrates BD's commitment to providing the best solutions to optimize lab efficiency and productivity that enable lab personnel to perform other tasks during a test run."
GBS remains one of the leading causes of morbidity and mortality among newborns, with maternal colonization serving as a major risk factor for early onset GBS disease. However, it is preventable with antibiotics during labor, which prevents transmission from mother to infant. The U.S. Centers for Disease Control and Prevention (CDC) recommends universal prenatal screening for GBS colonization and intrapartum chemoprophylaxis for colonized mothers in order to prevent transmission to infants. The current standard of care for preventing neonatal GBS disease is screening pregnant women at 35 to 37 weeks of gestation using culture methods, which are limited by sensitivity, turnaround time and the need for highly trained technologists to interpret the results.
"The BD MAX GBS assay on the BD MAX System is the only fully automated polymerase chain reaction method for the detection of GBS from vaginal/rectal swabs after Lim broth selective enrichment," said Dr. Steve Young, TriCore Reference Laboratories, a clinical trial site. "As new CDC guidelines emerge to include molecular testing as an alternative to culture for detecting GBS, the BD MAX GBS assay could serve as an efficient, sensitive and specific option for laboratories desiring to utilize a molecular method."
The BD MAX GBS assay on the BD MAX System represents a significant advance in neonatal healthcare by streamlining the GBS screening process and addressing the limitations of current culture methods by providing rapid, objective results. With no visual interpretation required, the BD MAX GBS assay identifies GBS in just over an hour from Lim broth, which can help ensure that colonization status is available in the case of preterm delivery. By automating sample lysis through polymerase chain reaction detection, the BD MAX System offers walkaway convenience for up to 24 samples in approximately two and a half hours.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
